Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA
How this was made
The 30-second read
Why it matters
The 8‑K provides the first public disclosure of Q3 financials and multiple trial initiations, which are material for valuation.
Market read
First‑time disclosure of cash runway to 2030 and active Phase 3 trial enrollment; likely to influence biotech investors and short‑term price action.
What to watch
Potential regulatory delays or trial enrollment challenges could offset the positive cash runway narrative.
Background
Trevi Therapeutics (Nasdaq: TRVI) is a clinical‑stage biopharma developing oral nalbuphine ER for chronic cough associated with IPF, non‑IPF ILD, and refractory chronic cough.
Ticker impact
SEC 8‑K disclosed Trevi Therapeutics' Q3 2026 results, cash runway to 2030 and initiation of Phase 3 OCEAN‑2 and Phase 2 non‑IPF ILD trials.
potential upside as cash runway extension and trial progress may lift sentiment, though a widening net loss could limit gains
New cash position and trial initiations are material for a clinical‑stage biotech; investors typically react positively to extended runway and active trial enrollment.
Market effects
Adds to positive momentum in the biotech sector as a peer reports cash runway and trial activity.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond biotech-focused funds.
Counterpoint
The widening net loss and reliance on future trial outcomes could keep the stock under pressure despite cash runway news.
Key entities
- ExecutiveJennifer Good
President and CEO of Trevi Therapeutics, quoted in the filing.
